Basis: FMP quote market capitalization / four-quarter operating cash flow. Source: stored company filings and market data; unavailable inputs remain N/A.
The Price/OCF ratio is N/A as of 2026-10-06T22:07:43.594Z.
Calculation as of: 2026-10-06T22:07:43.594Z.
Quote observation: 2026-10-06T20:00:00.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 88249fb6bbade3b4ad802b4bad00c79a42ee89cc3a650020707e3f27628c9d48
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
PRICE/OCF RATIO
N/A
Market Cap
$143.60M
Price/OCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$143.84M
Price/OCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$146.27M
Price/OCF Ratio
1.16
TTM Avg
4.90
3Y Avg
4.90
5Y Avg
4.90
Market Cap
$139.84M
Price/OCF Ratio
N/A
TTM Avg
64.59
3Y Avg
64.59
5Y Avg
39.56
Market Cap
$146.62M
Price/OCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | PRICE/OCF RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Nyxoah S.A. (NYXH) | $143.10M | N/A | N/A | N/A | N/A |
| Protara Therapeutics, Inc. (TARA)vs › | $143.60M | N/A | N/A | N/A | N/A |
| NervGen Pharma Corp. Common stock (NGEN)vs › | $143.84M | N/A | N/A | N/A | N/A |
| Fortress Biotech, Inc. (FBIOP)vs › | $146.27M | 1.16 | 4.90 | 4.90 | 4.90 |
| Codexis, Inc. (CDXS)vs › | $146.28M | N/A | 32.64 | 32.64 | 32.64 |
| Sutro Biopharma, Inc. (STRO)vs › | $139.84M | N/A | 64.59 | 64.59 | 39.56 |
| Acumen Pharmaceuticals, Inc. (ABOS)vs › | $146.62M | N/A | N/A | N/A | N/A |
| Alpha Cognition Inc (ACOG)vs › | $139.47M | N/A | N/A | N/A | N/A |
| Immuneering Corporation (IMRX)vs › | $139.04M | N/A | N/A | N/A | N/A |
| Anavex Life Sciences Corp. (AVXL)vs › | $148.27M | N/A | N/A | N/A | N/A |
P/OCF Ratio
N/A
P/FCF Ratio
N/A
P/OCF measures market price relative to operating cash flow: market cap divided by TTM operating cash flow. OCF is cash from operations before capital expenditures, so it sits above free cash flow — P/OCF typically reads below P/FCF, with the widest gap for capex-heavy businesses.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
